Here are relevant reports on : hypertension-drugs-market
-
Global Multiple Myeloma Drugs Market
2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate. There has been a significant development in technologies and drugs/vaccines with respect to breast cancer, thyroid cancer, and pancreatic cancer therefore increasing the survival rates.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Global Weight Loss Drugs, Supplements And Cosmetics Market
Individuals with high BMI have a greater risk of developing diseases such as cancer and diabetes. This holds true for both men and women; and those with BMI above 35 are at the highest risk. However, increasing awareness about obesity is encouraging consumers to seek medical assistance and consultation for weight reduction. The market for weight-loss drugs, cosmetics, and supplements is witnessing a significant growth as these do not involve strict diet or exercise regimens. Top pharmaceutical companies have thus increased R&D investments for anti-obesity drugs with minimal or no side effects.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Ophthalmology Drugs & Devices Market (Contact Lens, Optical Coherence Tomography (OCT) Scanner, IOL, Dry Eye, AMD, Glaucoma & Phacoemulsification) – Competitive Landscape & Global Forecasts To 2017
The global ophthalmology market witnessed a dip during the economic downturn in 2008 and 2009; however, it is poised to grow at a stable rate mainly due to an increasing aging population, large pool of patients with eye diseases, changing demographics and geographical trends, and increased focus on combination therapies of drugs. Moreover, incidences of glaucoma and cataract are increasing every year.
- Published: August 2012
- Price: $ 4950
- TOC Available:
-
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) - Global Forecast to 2026
The global cognition enhancement market is expected to grow from USD 23.4 billion in 2021 to USD 38.9 billion by 2026, at a compound annual growth rate (CAGR) of 10.7% during the forecast period.The leading players Eisai Co., Ltd. (Japan), Johnson & Johnson Services, Inc. (US), Biogen Inc. (US), Eli Lilly and Company (US), Nordic Naturals (US), Natrol, LLC (US), Cambridge Cognition Ltd. (UK), and Cogstate Ltd. (US).
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Europe Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Europe Oligonucleotide Synthesis market, valued at USD 2.68 billion in 2024, stood at USD 3.17 billion in 2025 and is projected to advance at a resilient CAGR of 18.7% from 2025 to 2030, culminating in a forecasted valuation of USD 7.49 billion by the end of the period. The market is growing due to strong demand from therapeutics, diagnostics, and research.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023
The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Oligonucleotide Synthesis Market by Product {Drugs [ASO, siRNA], Synthesized Oligos [Product (Primers, Probes), Type (Custom, Predesigned)], Reagents, Equipment}, Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Asia Pacific Oligonucleotide Synthesis market, valued at USD 1.76 billion in 2024, stood at USD 2.08 billion in 2025 and is projected to advance at a resilient CAGR of 18.5% from 2025 to 2030, culminating in a forecasted valuation of USD 4.88 billion by the end of the period. This expansion is driven by increasing demand from therapeutics, diagnostics, and research.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: June 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
